Not all partial dopamine D₂ receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse

References

• HowesODKapurSThe dopamine hypothesis of schizophrenia: version III – the final common pathwaySchizophr Bull200935354956219325164
   PubMed Web of Science ®Google Scholar
• HowesODMontgomeryAJAsselinMCElevated striatal dopamine function linked to prodromal signs of schizophreniaArch Gen Psychiatry2009661132019124684
   PubMed Web of Science ®Google Scholar
• KomossaKRummel-KlugeCSchmidFAripiprazole versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev200974CD00656919821375
   PubMed Web of Science ®Google Scholar
• CaseyDESandsEEHeisterbergJYangHMEfficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia, results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding studyPsychopharmacology (Berl)2008200331733118597078
   PubMed Web of Science ®Google Scholar
• CraggSJHilleCJGreenfieldSADopamine release and uptake dynamics within nonhuman primate striatum in vitroJ Neurosci200020218209821711050144
   PubMed Web of Science ®Google Scholar
• WuQReithMEWalkerQDKuhnCMCarrollFIGarrisPAConcurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission, an in vivo voltammetric studyJ Neurosci200222146272628112122086
   PubMed Web of Science ®Google Scholar
• TadoriYForbesRAMcQuadeRDKikuchiTReceptor reserve-dependent properties of antipsychotics at human dopamine D2 receptorsEur J Pharmacol200960713354019326565
   PubMed Web of Science ®Google Scholar
• PaniLPiraLMarcheseGAntipsychotic efficacy, relationship to optimal D2-receptor occupancyEur Psychiatry200722526727517419008
   PubMed Web of Science ®Google Scholar
• DahanLHusumHMnie-FilaliOArntJHertelPHaddjeriNEffects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviourJ Psychopharmacol200923217718918515444
   PubMed Web of Science ®Google Scholar
• BrownPOlivieroAMazzonePInsolaATonaliPDi LazzaroVDopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson’s diseaseJ Neurosci20012131033103811157088
   PubMed Web of Science ®Google Scholar
• ZhangLDoyonWMClarkJJPhillipsPEDaniJAControls of tonic and phasic dopamine transmission in the dorsal and ventral striatumMol Pharmacol200976239640419460877
   PubMed Web of Science ®Google Scholar
• MontaguePMcClureSBaldwinPDynamic gain control of dopamine delivery in freely moving animalsJ Neurosci20042471754175914973252
   PubMed Web of Science ®Google Scholar
• KoeltzowTEXuMCooperDCAlterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant miceJ Neurosci1998186223122389482807
   PubMed Web of Science ®Google Scholar
• PovlockSLSchenkJOA multisubstrate kinetic mechanism of dopamine transport in the nucleus accumbens and its inhibition by cocaineJ Neurochem1997693109311059282932
   PubMed Web of Science ®Google Scholar
• WaymentHSchenkJSorgBCharacterization of extracellular dopamine clearance in the medial prefrontal cortex, role of monoamine uptake and monoamine oxidase inhibitionJ Neurosci2001211354211150317
   PubMed Web of Science ®Google Scholar
• SeemanPTargeting the dopamine D2 receptor in schizophreniaExpert Opin Ther Targets200610451553116848689
   PubMed Web of Science ®Google Scholar
• KapurSVanderSpekSCBrownleeBANobregaJNAntipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancyJ Pharmacol Exp Ther2003305262563112606608
   PubMed Web of Science ®Google Scholar
• SautelFGriffonNLévesqueDPilonCSchwartzJCSokoloffPA functional test identifies dopamine agonists selective for D3 versus D2 receptorsNeuroreport1995623293327756621
   PubMed Web of Science ®Google Scholar
• PugsleyTADavisMDAkunneHCNeurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907J Pharmacol Exp Ther19952753135513668531103
   PubMed Web of Science ®Google Scholar
• HalldinCFardeLHögbergTCarbon-11-FLB 457, a radioligand for extrastriatal D2 dopamine receptorsJ Nucl Med1995367127512817790956
   PubMed Web of Science ®Google Scholar
• BrückeTTsaiYFMcLellanCIn vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM), a potential imaging ligand for D-2 dopamine receptors in SPECTLife Sci19884221209721043260318
   PubMed Web of Science ®Google Scholar
• DelforgeJBottlaenderMPappataSLoc’hCSyrotaAAbsolute quantification by positron emission tomography of the endogenous ligandJ Cereb Blood Flow Metab200121561363011333372
   PubMed Web of Science ®Google Scholar
• CatafauAMSuarezMBullichSWithin-subject comparison of striatal D2 receptor occupancy measurements using [123I] IBZM SPECT and [11C]Raclopride PETNeuroimage200946244745819233294
   PubMed Web of Science ®Google Scholar
• WoodMDScottCClarkeKAripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist propertiesEur J Pharmacol200654613889416914136
   PubMed Web of Science ®Google Scholar
• KimJRSeoHBChoJYPopulation pharmacokinetic modeling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patientsBr J Clin Pharmacol200866680281019032724
   PubMed Web of Science ®Google Scholar
• CosiCCarilla-DurandEAssiéMBPartial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors, G protein activation and prolactin releaseEur J Pharmacol20065351313514416527269
   PubMed Web of Science ®Google Scholar
• BurrisKDMolskiTFXuCAripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptorsJ Pharmacol Exp Ther2002302138138912065741
   PubMed Web of Science ®Google Scholar
• EtievantABétryCArntJHaddjeriNBifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activationNeurosci Lett20094601828619450663
   PubMed Web of Science ®Google Scholar
• ShapiroDARenockSArringtonEAripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacologyNeuropsychopharmacology20032881400141112784105
   PubMed Web of Science ®Google Scholar
• UsielloABaikJHRougé-PontFDistinct functions of the two isoforms of dopamine D2 receptorsNature2000408680919920311089973
   PubMed Web of Science ®Google Scholar
• SalzmanCRosenbergJFeldmanJJSchizophrenia symptoms remain stable during decreases from 2 antipsychotics to aripiprazoleJ Clin Psychiatry200768697017592928
   PubMed Web of Science ®Google Scholar
• KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry200263976377112363115
   PubMed Web of Science ®Google Scholar
• ChristensenAFPoulsenJNielsenCTBorkBChristensenAChristensenMPatients with schizophrenia treated with aripiprazole, a multicentre naturalistic studyActa Psychiatr Scand2006113214815316423167
   PubMed Web of Science ®Google Scholar
• TandonRMarcusRNStockEGA prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA)Schizophr Res2006841778916483745
   PubMed Web of Science ®Google Scholar
• PotkinSGSahaARKujawaMJAripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorderArch Gen Psychiatry200360768169012860772
   PubMed Web of Science ®Google Scholar
• CaseyDECarsonWHSahaARSwitching patients to aripiprazole from other antipsychotic agents, a multicenter randomized studyPsychopharmacology (Berl)2003166439139912610718
   PubMed Web of Science ®Google Scholar
• YokoiFGründerGBiziereKDopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]racloprideNeuropsychopharmacology200227224825912093598
   PubMed Web of Science ®Google Scholar
• KegelesLSSlifsteinMFrankleWGDose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallyprideNeuropsychopharmacology2008333111312518418366
   PubMed Web of Science ®Google Scholar
• ZimbroffDLKaneJMTammingaCAControlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study GroupAm J Psychiatry199715467827919167505
   PubMed Web of Science ®Google Scholar
• GomezJCCrawfordAMSuperior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trialJ Clin Psychiatry200162Suppl 261111232753
   PubMed Web of Science ®Google Scholar
• SikichLHamerRMBashfordRASheitmanBBLiebermanJAA pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trialNeuropsychopharmacology200429113314514583740
   PubMed Web of Science ®Google Scholar
• ZipurskyRBChristensenBKDaskalakisZTreatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosisCan J Psychiatry200550846246916127964
   PubMed Web of Science ®Google Scholar
• KapurSRemingtonGJonesCHigh levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET studyAm J Psychiatry199615379489508659621
   PubMed Web of Science ®Google Scholar
• KapurSZipurskyRBRemingtonGClinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophreniaAm J Psychiatry199915622862939989565
   PubMed Web of Science ®Google Scholar
• BernardoMParelladaELomenaFDouble-blind olanzapine vs haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpointPsychiatry Res20011072879711530275
   PubMed Web of Science ®Google Scholar
• LaruelleMD’SouzaCDBaldwinRMImaging D2 receptor occupancy by endogenous dopamine in humansNeuropsychopharmacology19971731621749272483
   PubMed Web of Science ®Google Scholar
• FisherREMorrisEDAlpertNFischmanAJIn vivo imaging of neuromodulatory synaptic transmission using PET, a review of relevant neurophysiologyHum Brain Mapp199532434
   Web of Science ®Google Scholar
• AbbottDHBarnettDKColmanRJYamamotoMESchultz-DarkenNJAspects of common marmoset basic biology and life history important for biomedical researchComp Med200353433935014524409
   PubMed Web of Science ®Google Scholar
• PerezXAParameswaranNHuangLZO’LearyKTQuikMPresynaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primatesJ Neurochem200810551861187218248617
   PubMed Web of Science ®Google Scholar
• FriedmanJHBermanRMGoetzCGOpen-label flexible- dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s diseaseMov Disord200621122078208117013906
   PubMed Web of Science ®Google Scholar
• QiZMillerGWVoitEOComputational systems analysis of dopamine metabolismPLoS One200836e244418568086
   PubMed Web of Science ®Google Scholar
• TauscherJKüfferleBAsenbaumSTauscher-WisniewskiSKasperSStriatal dopamine-2 receptor occupancy as measured with [123I] iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidolPsychopharmacology (Berl)20021621424912107616
   PubMed Web of Science ®Google Scholar
• LandBRSalpeterEESalpeterMMKinetic parameters for acetylcholine interaction in intact neuromuscular junctionProc Natl Acad Sci U S A19817811720072046947281
   PubMed Web of Science ®Google Scholar